Post-transplant cytomegalovirus (CMV) infection afflicts as high as 80% of kidney organ transplant recipients, resulting in life-threatening direct complications, long-term negative outcomes, and significant morbidity and mortality. Current first-line antivirals administered to patients in post-treatment prophylaxis are associated with toxicity that increases the risk of opportunistic infections and of graft rejection. Emerging therapies, however, have demonstrated lower toxicity rates in other disease states and present potential prophylaxis alternatives for the kidney transplant population. It is imperative that clinicians working in the transplant field are appraised on emerging therapies to provide the best possible standards of care.
In this CME Outfitters Live Webcast, expert faculty will guide learners through the implications of CMV infection as well as strategies to individualize and optimize CMV prevention in kidney transplant recipients. Faculty will also help learners to implement an interprofessional team approach, including institutional policies or protocols, to support optimal use of CMV prophylaxis therapies.
Supported by an educational grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Transplant specialists/surgeons, ID specialists, transplant and ID pharmacists, nurse practitioners (NPs), physician associates (PAs), hospitalists, internists, primary care physicians, and nurses
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.
CME Outfitters, LLC, designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designated for 1.00 contact hours.
This application-based activity is approved for 1.00 contact hours ( 0.1 CEUs) of continuing pharmacy credit ( JA0007185-0000-23-134-H01-P ).
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 11/29/2024. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Kaul reports the following financial relationships:
Research Support: AstraZeneca; Janssen Pharmaceuticals, Inc.; Nobelpharma America, LLC.; and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Bloom reports the following financial relationships:
Research Support: CSL Behring; CareDX; Memo Therapeutics AG; Natera, Inc.; and Veloxis Pharmaceuticals, Inc.
Other financial or material support: Royalty: UpToDate, Inc.
Dr. Jorgenson reports no financial relationships to disclose.
Disclosures were obtained from the following peer reviewer and CME Outfitters, LLC, staff, with no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.
Call us at 877.CME.PROS (877.263.7767).
WCV-079-112923-44